Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 88.2%

Neg 0% Neu 0% Pos 88.2%

Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.